KR20190018677A - 생물학적 시스템용 조성물 및 그의 제조 및 사용 방법 - Google Patents

생물학적 시스템용 조성물 및 그의 제조 및 사용 방법 Download PDF

Info

Publication number
KR20190018677A
KR20190018677A KR1020197000781A KR20197000781A KR20190018677A KR 20190018677 A KR20190018677 A KR 20190018677A KR 1020197000781 A KR1020197000781 A KR 1020197000781A KR 20197000781 A KR20197000781 A KR 20197000781A KR 20190018677 A KR20190018677 A KR 20190018677A
Authority
KR
South Korea
Prior art keywords
composition
volume
cells
solution
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020197000781A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 디. 존스
네이션 퀸타나
로산 파텔
Original Assignee
스마트 서지컬, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스마트 서지컬, 인크. filed Critical 스마트 서지컬, 인크.
Publication of KR20190018677A publication Critical patent/KR20190018677A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
KR1020197000781A 2016-06-13 2017-06-12 생물학적 시스템용 조성물 및 그의 제조 및 사용 방법 Abandoned KR20190018677A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662349633P 2016-06-13 2016-06-13
US62/349,633 2016-06-13
US15/619,467 2017-06-10
US15/619,467 US10426796B2 (en) 2016-06-13 2017-06-10 Compositions for biological systems and methods for preparing and using the same
PCT/US2017/037055 WO2017218427A1 (en) 2016-06-13 2017-06-12 Compositions for biological systems and methods for preparing and using the same

Publications (1)

Publication Number Publication Date
KR20190018677A true KR20190018677A (ko) 2019-02-25

Family

ID=60572084

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197000781A Abandoned KR20190018677A (ko) 2016-06-13 2017-06-12 생물학적 시스템용 조성물 및 그의 제조 및 사용 방법

Country Status (9)

Country Link
US (4) US10426796B2 (https=)
EP (1) EP3468570A4 (https=)
JP (1) JP2019521113A (https=)
KR (1) KR20190018677A (https=)
CN (1) CN109562130A (https=)
AU (1) AU2017284186A1 (https=)
CA (1) CA3026575A1 (https=)
MX (1) MX2018015388A (https=)
WO (1) WO2017218427A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10456423B2 (en) * 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
CN108823160B (zh) * 2018-07-25 2020-08-21 广州赛莱拉干细胞科技股份有限公司 一种脐带间充质干细胞原代培养基及其原代培养方法
CN109628406B (zh) * 2019-01-03 2021-02-26 北京贝来生物科技有限公司 一种治疗自身免疫疾病的间充质干细胞及其制备方法和应用
CN114452285B (zh) * 2022-02-17 2022-11-25 中国中医科学院中药研究所 一种il-17a拮抗剂在治疗糖尿病溃疡中的用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525519A (en) 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
ES2157260T3 (es) 1993-06-04 2001-08-16 Biotime Inc Solucion semejante a plasma.
US5543316A (en) 1994-04-20 1996-08-06 Diacrin, Inc. Injectable culture medium for maintaining viability of myoblast cells
JPH11322618A (ja) * 1998-05-13 1999-11-24 Asahi Medical Co Ltd 有核細胞分離回収方法及び有核細胞含有液
JP4061775B2 (ja) * 1998-05-21 2008-03-19 ニプロ株式会社 アルブミン含有腹膜透析液
US6153582A (en) 1998-11-05 2000-11-28 Bausch & Lomb Surgical, Inc. Defined serumfree medical solution for ophthalmology
US6899889B1 (en) 1998-11-06 2005-05-31 Neomend, Inc. Biocompatible material composition adaptable to diverse therapeutic indications
US7020845B1 (en) * 1999-11-15 2006-03-28 Gottfurcht Elliot A Navigating internet content on a television using a simplified interface and a remote control
US7274368B1 (en) * 2000-07-31 2007-09-25 Silicon Graphics, Inc. System method and computer program product for remote graphics processing
CN100553636C (zh) * 2000-08-04 2009-10-28 Dmi生物科学公司 二酮基哌嗪和包含它们的组合物的使用方法
DK1349918T3 (da) 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
IL158171A0 (en) 2001-04-10 2004-03-28 Bioergonomics Inc Compositions and methods for cell separation
US20030099621A1 (en) * 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection
US7771716B2 (en) * 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US20110280838A1 (en) 2007-12-27 2011-11-17 Advanced Technologies And Regenerative Medicine, Llc Treatment of intervertebral disc degeneration using human umbilical cord tissue-derived cells
CA2581424A1 (en) 2004-03-09 2005-09-22 Gang Xu Methods for generating insulin-producing cells
US7622108B2 (en) * 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
US7670596B2 (en) 2004-04-23 2010-03-02 Bioe, Inc. Multi-lineage progenitor cells
JP2007536936A (ja) 2004-05-14 2007-12-20 ベクトン・ディキンソン・アンド・カンパニー 幹細胞集団および使用方法
WO2007019678A1 (en) * 2005-08-12 2007-02-22 University Health Network Methods and devices for lymphatic targeting
SE529040C2 (sv) * 2006-01-18 2007-04-17 Bows Pharmaceuticals Ag Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin
CA2646491A1 (en) 2006-04-17 2007-10-25 Bioe, Inc. Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
US9598673B2 (en) * 2006-05-19 2017-03-21 Creative Medical Health Treatment of disc degenerative disease
WO2007134461A1 (en) * 2006-05-24 2007-11-29 Titan Medical Inc. Snaking robotic arm with movable shapers
WO2008034803A1 (en) 2006-09-18 2008-03-27 Medizinische Universität Graz Plasma-free platelet lysate for use as a supplement in cell cultures and for the preparation of cell therapeutics
US8465733B2 (en) * 2007-11-02 2013-06-18 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition containing human mesenchymal stem cell
US20090229463A1 (en) 2008-02-15 2009-09-17 Coalstar Industries, Inc. Apparatus and processes for production of coke and activated carbon from coal products
HU0800134D0 (en) * 2008-02-26 2008-04-28 Semmelweis Egyetem Procedure for producing mineralized bone composition
CA2724839A1 (en) 2008-05-21 2009-11-26 Bioe Llc Differentiation of multi-lineage progenitor cells to pancreatic cells
US20120093782A1 (en) * 2009-05-13 2012-04-19 Grove Robert I Enhanced Hematopoietic Stem Cell Engraftment
US9168442B2 (en) * 2009-09-21 2015-10-27 Thomas M. Covino Gaming surface and game styled after american football
EP2483392B1 (en) 2009-09-23 2015-11-11 Davinci Biosciences LLC Umbilical cord lining stem cells and methods and material for isolating and culturing same
CA2802203A1 (en) * 2010-06-10 2011-12-15 Aastrom Biosciences, Inc. Compositions and methods of treating no-option critical limb ischemia (cli)
US20130323712A1 (en) 2010-11-25 2013-12-05 Kaneka Corporation Method and material for separating leukocytes or mononuclear cells
CA2774383A1 (en) 2011-06-22 2012-12-22 Shaf Keshavjee Repaired organ and method for making the same
WO2013134464A1 (en) * 2012-03-07 2013-09-12 Children's Medical Center Corporation Tissue constructs and uses thereof
SG11201407768QA (en) 2012-04-24 2015-01-29 Brigham & Womens Hospital Generating pluripotent cells de novo
CN104094557A (zh) * 2012-05-30 2014-10-08 株式会社东芝 铁路车辆用传送装置、铁路车辆、控制方法以及控制程序
US9283084B1 (en) 2012-07-24 2016-03-15 Thomas E. O'Hara Spinal fusion cage and vertebral body clamp
CN102920734A (zh) * 2012-11-14 2013-02-13 青岛奥克生物开发有限公司 一种间充质干细胞注射液及其制备方法和在制备治疗溃疡性结肠炎药物中的应用
AU2013364097A1 (en) * 2012-12-18 2015-07-02 Robert Chow Blood cell preparations and related methods (GEN 8)
SG11201505965TA (en) 2013-01-31 2015-09-29 Ajinomoto Kk Culture method for stable undifferentiated proliferation of pluripotent stem cells
SG11201505715RA (en) * 2013-02-01 2015-08-28 Ampio Pharmaceuticals Inc Methods for producing diketopiperazines and compositions containing diketopiperazines
US9241959B2 (en) 2013-03-13 2016-01-26 Mingqi TANG Kits and methods for processing stem cells from bone marrow or umbilical cord blood
SG11201507515YA (en) 2013-03-15 2015-10-29 Marcus Kare Torleif Larsson Cells, methods and apparatuses for umbilical cord blood collection and isolation of cells
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
BR112015020469A2 (pt) * 2013-03-15 2020-01-28 Ampio Pharmaceuticals Inc Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
KR20220044384A (ko) 2013-10-03 2022-04-07 안트로제네시스 코포레이션 사람 태반으로부터의 세포 및 조혈 세포를 사용한 치료
US9238984B2 (en) * 2014-02-03 2016-01-19 Caterpillar, Inc. Exhaust emission prediction system and method
US20170319747A1 (en) * 2014-10-31 2017-11-09 Kyoto University Three-dimensional culture method using biodegradable polymer and culture substrate enabling cell transplantation
CN115777690A (zh) * 2014-11-14 2023-03-14 日本赤十字社 脐带血以及末梢血的冻结保存方法以及冻结保存用溶液
IL297773B2 (en) * 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
TWI548748B (zh) 2015-04-16 2016-09-11 台灣尖端先進生技醫藥股份有限公司 造血幹／先驅細胞之體外放大培養方法及其立即可使用之組成物
KR20180021736A (ko) 2015-06-15 2018-03-05 바이탈 쎄러피스, 인코포레이티드 세포의 항아폽토시스, 생존, 또는 증식을 유도하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
US10363271B2 (en) 2019-07-30
EP3468570A1 (en) 2019-04-17
AU2017284186A1 (en) 2019-01-03
JP2019521113A (ja) 2019-07-25
CA3026575A1 (en) 2017-12-21
US20190328789A1 (en) 2019-10-31
US10213463B2 (en) 2019-02-26
EP3468570A4 (en) 2020-01-01
US20170354683A1 (en) 2017-12-14
MX2018015388A (es) 2019-04-29
US10426796B2 (en) 2019-10-01
US20170354684A1 (en) 2017-12-14
WO2017218427A1 (en) 2017-12-21
CN109562130A (zh) 2019-04-02
US20180264041A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
Muschler et al. Selective retention of bone marrow-derived cells to enhance spinal fusion.
AU2014238305B2 (en) Methods and non-immunogenic compositions for treating inflammatory disorders
EP3074507B1 (en) Methods of mediating macrophage phenotypes
CA2916158C (en) Treatment of peripheral vascular disease using protein solutions
US20160074479A1 (en) Methods of treating spinal disorders using autologous protein solutions
CA2916190C (en) Treatment of collagen defects using protein solutions
KR20190018677A (ko) 생물학적 시스템용 조성물 및 그의 제조 및 사용 방법
US11369640B2 (en) Compositions for biological systems and methods for preparing and using the same
KR20210091760A (ko) 혈소판 방출물의 제조방법
Freitas et al. Freeze-dried platelet-rich plasma and stem cell-conditioned medium for therapeutic use in horses
CN109985064B (zh) 间充质干细胞分泌提取物的用途、间充质干细胞分泌提取物及其制备方法
Ruiz et al. New formulations of platelet-rich plasma: the relevance of extraplatelet molecules
Vun et al. The in vitro effects of platelet products on the biophysiological functions of human bone marrow mesenchymal stromal cells: a systematic review
AU2018281936A1 (en) Compositions for biological systems and methods for preparing and using the same
CA3171694C (en) Method for producing enhanced anti-inflammatory/anti-catabolic agents from autologous physiological fluid
EP3161479B1 (en) Methods for assessing the efficacy of anti-inflammatory cytokine compositions
Leung et al. Osteochondral tissue engineering for osteoarthritis using infrapatellar fat-pad derived mesenchymal stem cells
JP6094761B2 (ja) 自己タンパク質の製造方法
Ruiz et al. Relevance of Extraplatelet
Bastian et al. Local and systemic chemokine patterns in a human musculoskeletal trauma model
Radzali et al. Preparation and in vitro wound healing effects of animal-based platelet-rich plasma lysate
Strafun et al. Quality criteria for minimally manipulated biotechnological products based on autologous bone marrow aspirate for use in traumatology and orthopedics
US20190224239A1 (en) Heat-exposed platelet lysate compositions, and methods for preparing and using same
DE102021124752A1 (de) Autologes Therapeutikum und Verfahren zur Herstellung desselben
JP2002080378A (ja) マクロファージを含む細胞製剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000